FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer

(2019) Sasagu Kurozumi et al.   Scientific Reports

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

(2019) Sasagu Kurozumi et al.   Scientific Reports

Metabolic Consequences of T-cell Costimulation in Anticancer Immunity

(2019) Alvaro Teijeira et al.   Cancer Immunology Research

Immunotherapeutic interventions of Triple Negative Breast Cancer

(2018) Zehuan Li et al.   Journal of Translational Medicine

Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer

(2018) TAKAAKI FUJII et al.   ANTICANCER RESEARCH

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer

(2017) Sasagu Kurozumi et al.   Medical Molecular Morphology

Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses

(2017) Seungho Lee et al.   Journal of Gastric Cancer

Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma

(2016) TAKAAKI FUJII et al.   ANTICANCER RESEARCH

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery

(2016) Egesta Lopci et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

(2016) Weijie Ma et al.   Journal of Hematology & Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells

(2016) Nikolaos Svoronos et al.   Cancer Discovery

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2015) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Recommendations on the Use of 18F-FDG PET in Oncology

(2008) J. W. Fletcher et al.   JOURNAL OF NUCLEAR MEDICINE